aTyr Pharma, Inc. (ATYR)
Develops experimental drugs using tRNA biology to treat lung fibrosis and inflammation diseases.
$0.49+0.01%Healthcare
StockGlow Score
Leaning Bearish
BearishBullish
1 year ago-89.5%
The outlook
ATYR is trading near its 52-week lows, well below both its short and long-term moving averages. Analysts lean bullish with a buy consensus, though coverage is modest at 7 analysts. The wide gap between the current price and the average price target suggests significant analyst optimism, but the stock's position at the bottom of its annual range reflects current market weakness.
What’s behind the score
Analyst consensusBuy — 2.3 avg of 7 analysts
Price trendBelow its 50- & 200-day averages
52-week range2% of the way from its 52-week low to high
Price targetAvg target +478% vs current price
Analyst price target
~12-month · 7 analysts$2.86average target+478.4% vs now
Now $0.49
Low $1.00High $7.00
Published targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.
Market cap
$48.4M
52-wk high
$6.50
52-wk low
$0.40
50-day avg
$0.51
200-day avg
$0.75
Trailing P/E
—